Importance of tumor size in resectable stage III-N2 non–small cell lung cancer

Simple item page
dc.contributor.authorPérez Castro, Pablo
dc.contributor.authorPerrot, Marc de
dc.contributor.authorChua, Yang Chong
dc.contributor.authorBezjak, Andrea
dc.contributor.authorLeighl, Natasha
dc.contributor.authorDarling, Gail
dc.contributor.authorPierre, Andrew
dc.contributor.authorYasufuku, Kazuhiro
dc.contributor.authorCypel, Marcelo
dc.contributor.authorWaddell, Thomas
dc.contributor.authorDonahoe, Laura
dc.contributor.authorYeung, Jonathan
dc.contributor.authorKeshavjee, Shaf
dc.date.accessioned2022-06-09T17:05:55Z
dc.date.available2022-06-09T17:05:55Z
dc.date.issued2022
dc.description.abstractObjective The 8th TNM edition classifies stage III-N2 disease as IIIA and IIIB based on a tumor size cutoff of 5 cm. However, the importance of tumor size on survival in patients with resectable stage III-N2 disease has not been analyzed systematically. Methods Survival analysis based on tumor size (>5 cm vs ≤ 5 cm) for 255 consecutive patients with nonbulky (maximal lymph node diameter of 1.5 cm) stage III-N2 non–small cell lung cancer treated with surgery in our institution. Results Ninety patients (35.3%) underwent induction chemoradiation therapy (n = 72, 28%) or induction chemotherapy (n = 18, 7%), and 165 patients underwent primary surgery followed by adjuvant chemotherapy (n = 52, 32%), adjuvant chemoradiation therapy (n = 47, 29%), or adjuvant radiation therapy (n = 14, 13.2%). After a median follow-up of 6.5 years, the overall survival was 46.5% at 5 years and 28.9% at 10 years. In tumors 5 cm or less, there was no difference in survival between patients treated with induction or adjuvant therapy. However, in tumors greater than 5 cm, the survival was significantly better after induction therapy compared with adjuvant therapy or surgery alone. Pathologic multi-station N2 disease was more frequently detected in tumors greater than 5 cm (31% vs 18% in tumors ≤5 cm, P = .042), and the rate of R1 resection was lower after induction therapy (2.2% vs 8.5% in primary surgery, P = .048). Conclusions These results support the redefinition of tumors greater than 5 cm with resectable N2 disease to stage IIIB. This change should help to refine the multimodality approach for stage III-N2 lung cancer.es
dc.description.versionVersión Publicadaes
dc.identifier.citationPablo Perez Castro, Marc de Perrot, Yang Chong Chua, Andrea Bezjak, Natasha Leighl, Gail Darling, Andrew Pierre, Kazuhiro Yasufuku, Marcelo Cypel, Thomas Waddell, Laura Donahoe, Jonathan Yeung, Shaf Keshavjee, Importance of tumor size in resectable stage III-N2 non–small cell lung cancer, The Journal of Thoracic and Cardiovascular Surgery, 2022, , ISSN 0022-5223, https://doi.org/10.1016/j.jtcvs.2022.02.015.es
dc.identifier.urihttps://doi.org/10.1016/j.jtcvs.2022.02.015es
dc.identifier.urihttp://hdl.handle.net/11447/6196
dc.language.isoenes
dc.subjectLung cancer chemotherapyes
dc.subjectLung cancer radiationes
dc.subjectNon–small cell lung canceres
dc.subjectN2 diseasees
dc.subjectThoracic surgeryes
dc.titleImportance of tumor size in resectable stage III-N2 non–small cell lung canceres
dc.typeArticlees
dcterms.sourceThe Journal of Thoracic and Cardiovascular Surgeryes

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1-s2.0-S0022522322001957-main (1).pdf
Size:
1.29 MB
Format:
Adobe Portable Document Format
Description:
Texto completo restringido
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services